Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: Is it cost-effective?

Medical Journal of Australia

Volumn 177, Issue 8, 2002, Pages 428-434

  Glasziou, Paul P ^a   Eckermann, Simon D ^b   Mulray, Sarah E ^b   Simes, R John ^b   Martin, Andrew J ^b,c   Kirby, Adrienne C ^b   Hall, Jane P ^e   Caleo, Susan ^b,d   White, Harvey D ^f   Tonkin, Andrew M ^g  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Vitamin and Fine Chemicals Division   (Australia)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^f GREEN LANE HOSPITAL   (New Zealand)

^g NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG; FIBRIC ACID DERIVATIVE; GASTROINTESTINAL AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCULOSKELETAL SYSTEM AGENT; PLACEBO; PRAVASTATIN; PSYCHOTROPIC AGENT; RESIN; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG;

ABSENTEEISM; ADULT; AGED; ANAMNESIS; ARTICLE; AUSTRALIA AND NEW ZEALAND; CALCULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; OUTPATIENT CARE; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESOURCE MANAGEMENT; SOCIOECONOMICS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; UNSTABLE ANGINA PECTORIS;

EID: 0037152948     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2002.tb04883.x     Document Type: Article

References (17)

1. Hunink M, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-542.
2. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
5. Henry D. Economic analysis as an aid to subsidisation decisions: The development of Australian guidelines for pharmaceuticals. Pharmacoeconomics 1992; 1: 54-67.
6. Glasziou PP, Simes RJ, Hall J, Donaldson C. Design of a cost effectiveness study within a randomized trial: The LIPID trial for secondary prevention of IHD. Control Clin Trials 1997; 18: 464-476.
7. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department of Health and Ageing, Mar 1999.
8. Commonwealth of Australia. Manual of Resource Items and their Association Costs. Canberra: AGPS, 1992: 1-24.
9. Commonwealth Department of Health and Ageing. Medical Benefits Schedule (MBS). Availabe at www.health.gov.au/pubs/mbs/
10. Commonwealth Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Available at www1.health.gov.au/pbs/
11. Martin A, Glasziou PP, Simes RJ. A cardiovascular extension of the health measurement questionnaire. J Epidemiol Community Health 1999; 53: 548-557.
12. Martin A, Glasziou PP, Simes RJ. Lumley T. Predicting patient's utilities from quality of life items: An improved scoring system for the UBQ-H. Qual Life Res 1998; 7: 703-711.
13. Briggs A, O'Brien B, Blackhouse G. Thinking outside the box: Recent advances in the analysis and presentation of uncertainty in cost effectiveness studies. Annu Rev Public Health 2002; 23: 377-401.
14. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002; 359: 1379-1387.
15. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol in patients with coronary heart disease. N Engl J Med 1997; 336: 332-336.
16. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population. BMJ 1996; 312: 1443-1448.
17. Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature. Health Econ 2001; 10: 601-615.